Treating Patients With Poor-Risk Rcc

Treating Patients With Poor-Risk RCC

Treatment Options for Intermediate/Poor-Risk RCC

In RCC, What Is the Optimal Treatment for Intermediate/Poor-Risk Disease?

GU Oncology Now

Selecting Therapy for Poor-Risk Advanced RCC

Targeted Oncology

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Oncology

First-Line Treatment of Poor-Risk Metastatic Renal Cell Carcinoma

Poor-Risk Advanced RCC: TKI Therapy & Outlook

Targeted Oncology

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Candid Conversations on Modern Urothelial Cancer Management

PeerView Oncology

Second-Line Options for Poor-Risk Advanced RCC

Targeted Oncology

Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

High-Risk Renal Cell Carcinoma Treatment

Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023

Touch Medical Media Services

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC

PeerView Oncology

Will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?

UROwebinar: Management of Metastatic kidney cancer

European School of Urology

Renal Cell Carcinoma

University of California Television (UCTV)

Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC

Renal Cell Carcinoma: Past, Present, and Future

UNC Lineberger Cancer Network

Treating Intermediate and Favorable-Risk Renal Cell Carcinoma